StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-13 | $106.51 | $117.95 | +10.74% | 0.9M |
| 05-14 | $117.95 | $116.16 | -1.52% | 0.6M |
| 05-15 | $118.58 | $108.64 | -8.38% | 0.4M |
| 05-18 | $108.64 | $105.80 | -2.61% | 0.4M |
| 05-19 | $102.92 | $107.95 | +4.89% | 0.1M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
| Metric | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 |
|---|---|---|---|---|
Revenue | $1.30M | $1.30M | $1.30M | $0.00 |
Operating Income | $-135.03M | $-104.10M | $-70.29M | $-42.90M |
Net Income | $-140.06M | $-107.22M | $-28.65M | $-43.31M |
EPS (Diluted) | $-9.04 | $-6.93 | $-4.65 | $-2.80 |
Total Assets | $146.48M | $177.47M | $212.12M | $242.64M |
Total Liabilities | $138.49M | $140.64M | $143.56M | $148.20M |
Cash & Equivalents | $124.22M | $153.09M | $186.57M | $216.52M |
Free Cash Flow OCF − CapEx | $-129.82M | $-99.70M | $-65.87M | $-35.92M |
Shares Outstanding | 14.58M | 14.50M | 14.48M | 14.48M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.